Rescue therapy with an albuvirtide-based antiretroviral regimen in an HIV-infected child with multidrug resistance and multiple opportunistic infections: a case report

[1]  Q. Zheng,et al.  Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study. , 2022, The Journal of infection.

[2]  Marcin Grajewski.  Global and regional trends , 2021, COVID-19 and E-commerce.

[3]  C. Katlama,et al.  Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen , 2017, The Journal of antimicrobial chemotherapy.

[4]  Á. Holguín,et al.  Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review. , 2014, The Journal of antimicrobial chemotherapy.

[5]  C. Stephan,et al.  Impact of baseline HIV‐1 RNA levels on initial highly active antiretroviral therapy outcome: a meta‐analysis of 12,370 patients in 21 clinical trials * , 2013, HIV medicine.

[6]  Yuxian He,et al.  Biophysical Property and Broad Anti-HIV Activity of Albuvirtide, a 3-Maleimimidopropionic Acid-Modified Peptide Fusion Inhibitor , 2012, PloS one.

[7]  A. Phillips,et al.  Risk of triple-class virological failure in children with HIV: a retrospective cohort study , 2011, The Lancet.

[8]  A. Telenti,et al.  CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. , 2003, Archives of internal medicine.